HC Wainwright Reaffirms Buy Rating for Viking Therapeutics, Inc. (VKTX)

HC Wainwright reiterated their buy rating on shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in a research note issued to investors on Friday morning, Marketbeat.com reports. HC Wainwright currently has a $7.00 target price on the biotechnology company’s stock.

VKTX has been the subject of several other research reports. Maxim Group reaffirmed a buy rating and set a $5.00 target price on shares of Viking Therapeutics in a research note on Monday, September 11th. ValuEngine lowered Viking Therapeutics from a sell rating to a strong sell rating in a report on Friday, July 28th.

Shares of Viking Therapeutics (NASDAQ:VKTX) traded up $0.55 during mid-day trading on Friday, hitting $2.74. The stock had a trading volume of 1,277,700 shares, compared to its average volume of 312,075. Viking Therapeutics has a 12 month low of $0.88 and a 12 month high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). sell-side analysts expect that Viking Therapeutics will post -0.81 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “HC Wainwright Reaffirms Buy Rating for Viking Therapeutics, Inc. (VKTX)” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/11/14/hc-wainwright-reaffirms-buy-rating-for-viking-therapeutics-inc-vktx.html.

Hedge funds have recently bought and sold shares of the company. Sabby Management LLC bought a new position in shares of Viking Therapeutics in the second quarter valued at approximately $525,000. Virtu KCG Holdings LLC bought a new stake in Viking Therapeutics during the second quarter worth $124,000. Citadel Advisors LLC bought a new stake in Viking Therapeutics during the third quarter worth $108,000. Sphera Funds Management LTD. bought a new stake in Viking Therapeutics during the third quarter worth $554,000. Finally, Renaissance Technologies LLC lifted its holdings in Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 102,600 shares during the period. Institutional investors own 5.54% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply